Press release
Oxford Biomedica rebrands as
OXB reinforcing transformation into leading global cell and gene
therapy CDMO
Oxford, UK - 18 September
2024: OXB (LSE:OXB), a quality
and innovation-led cell and gene therapy CDMO, today announces the
launch of its new corporate brand.
Oxford Biomedica is rebranding as
OXB, unveiling a more modern and recognisable visual identity that
reinforces its transformation into a global pure-play cell and gene
therapy CDMO. The new identity reflects OXB's unique combination of
technical excellence, innovation and unwavering commitment to
deliver consistent high quality at every stage of viral vector
development and manufacturing. The new branding represents the
agile execution and creativity that enable OXB to deliver on
clients' goals, while also conveying accountability,
professionalism and teamwork - core values that underpin OXB's
mission.
Dr.
Frank Mathias, Chief Executive Officer of OXB,
commented: "The launch of our new brand identity
reinforces OXB's significant transformation into a leading
pure-play cell and gene therapy CDMO. This rebranding is more than
just a new look - it reflects the global nature of our operations
and our deep commitment to the success of our clients' drug
development programmes. As OXB, with our new capabilities and
global footprint, we are ideally positioned to communicate our
end-to-end services to current and potential clients, and to
interact with them from early-stage development through to
commercial manufacturing."
-Ends-
Enquiries:
OXB:
Sebastien Ribault, Chief Commercial
Officer - T: +44 (0) 1865 783 000 / E:
partnering@oxb.com
ICR
Consilium:
T: +44 (0)20 3709 5700 /
E: oxb@icrhealthcare.com
Mary-Jane Elliott / Angela Gray /
Davide Salvi
About OXB
OXB (LSE:
OXB) is a quality and innovation-led contract development and
manufacturing organisation (CDMO) in cell and gene therapy with a
mission to enable its clients to deliver life changing therapies to
patients around the world.
One of the original pioneers in cell
and gene therapy, OXB has more than 25 years of experience in viral
vectors; the driving force behind the majority of cell and gene
therapies. OXB collaborates with some of the world's most
innovative pharmaceutical and biotechnology
companies, providing viral vector development and manufacturing
expertise in lentivirus, adeno-associated virus (AAV), adenovirus,
and other viral vector types. OXB's world-class capabilities span
from early-stage development to
commercialisation. These capabilities are
supported by robust quality-assurance systems, analytical methods
and depth of regulatory expertise.
OXB offers a vast number of unique
technologies for viral vector manufacturing, including a 4th
generation lentiviral vector system (the
TetravectaTM
system), dual plasmid system for AAV production,
suspension and perfusion process using process enhancers and stable
producer and packaging cell lines.
OXB, a FTSE4Good constituent, is
headquartered in Oxford, UK. It has bioprocessing and manufacturing facilities across Oxfordshire, UK,
Lyon and Strasbourg, France, and near Boston, MA, US. Learn more
at www.oxb.com, and follow us
on LinkedIn and YouTube.